ACRx Stifel Investment Opportunity | Prescription Access Funding Teaser
ACRx Program · Card #ACRX103
Presented by Stifel Financial Corp.

$578 Billion Market.
20 Years of Proof.

The ACRx prescription discount card program is raising its first major institutional funding round — advised by Stifel Financial — to scale America's most trusted nonprofit prescription access network.

Official Major Teaser · October 3, 2024 · Stifel Financial Corp. — Exclusive Financial Advisor

Watch the pitch · then apply below

$578B
Total Addressable Market
25M+
Cards Distributed
20+
Years Operating
67K+
Pharmacy Locations
ACRx Stifel Final Major Teaser for Funding
Official document — October 3, 2024 · Stifel Financial Corp.

Detailed financial documents are available to qualified parties following NDA execution.

Request Access to Investment Documents
Funding Round

Raising $75 Million

Growth capital to scale America's most trusted prescription discount network — with institutional-grade oversight from Stifel Financial.

$75M
Funding Target
5–8x
Target ROIC
$2.75
Revenue / Prescription
75%
Avg. Discount to Members
Use of Proceeds
1

Scale national digital marketing and card distribution infrastructure

2

Expand proprietary AI-driven pharmacy pricing engine

3

Hire executive sales force for B2B and municipal partnerships

4

Strategic acquisition of regional PBM networks to increase margin per transaction

Revenue Model
Revenue per prescription $2.75
Avg. prescriptions per card/year 4.2
Revenue per active card/year $11.55

Revenue generated via standard PBM adjudication fee paid to ACRx for every transaction processed using Group ACRX103. Zero cost to cardholder.

Financial Projections

Growth Trajectory

Post-funding projections based on scaled distribution of Group ACRX103 cards via digital, B2B, and community channels.

Period Cards Distributed Projected Revenue YoY Growth
Year 1 (Post-Funding) 30,000,000 $48,500,000 Baseline
Year 2 45,000,000 $82,000,000 +69%
Year 3 65,000,000 $145,000,000 +77%

Digital Distribution Scale

SMS, QR codes, and social channels enable card distribution at near-zero cost per acquisition.

Municipal & Nonprofit Partnerships

Existing relationships with 50,000+ nonprofits, churches, schools, and hospitals provide instant distribution channels.

Recession-Resistant Model

Prescription demand is structurally inelastic. Economic downturns increase card adoption as budgets tighten.

Market Opportunity

A $578 Billion problem
with a 20-year proven solution

The Crisis

  • 28M+ Americans uninsured — requiring out-of-pocket prescription solutions
  • 1 in 3 Americans skip or ration medications due to cost
  • Prescription drug costs rising 5–9% annually, outpacing inflation
  • Low-income and rural families hit hardest — least access to savings programs

The ACRx Solution

  • Free card (Group ACRX103, BIN 018935, PCN ARX) accepted at 67,000+ pharmacies
  • Average 75% discount vs. retail — zero cost to the cardholder
  • Backed by ACRx nonprofit — 20+ years of operational credibility since 2004
  • Legacy BIN/PCN data ensures instant pharmacy recognition — zero friction
  • Revenue flows through PBM fee adjudication — scalable, repeatable, predictable
How the Revenue Model Works
1

Card Distributed

Physical or digital card shared via community, nonprofit, and digital channels

2

Rx Filled

Member uses card at any of 67,000+ participating pharmacies

3

PBM Fee Paid

$2.75 adjudication fee paid by the PBM to ACRx per prescription processed

4

Revenue Distributed

Revenue flows to program, investors, and community partners

Investment Case

Why ACRx

20-Year Track Record

Founded 2004. Established PBM relationships, BIN/PCN infrastructure, and 25M+ cards already in circulation. This is not a startup — it's a scaled, validated network seeking growth capital.

Low Overhead Nonprofit Model

Nonprofit structure drives higher consumer trust and lower user acquisition costs. Legacy BIN/PCN data eliminates pharmacy onboarding friction entirely.

Recession-Resistant Asset Class

Prescription demand is structurally inelastic regardless of economic climate. Downturns increase card adoption as patient budgets tighten — making this countercyclical.

ESG — Genuine Community Impact

Strong ESG credentials under LTC La Daryl Franklin's leadership. 50,000+ nonprofits, churches, schools, and hospitals already distributing the card create a self-reinforcing distribution moat.

Stifel-Backed Institutional Structure

Stifel Financial Corp. serves as exclusive lead financial advisor and placement agent for this growth capital round. This institutional-grade oversight facilitates institutional investor entry and provides a clear exit strategy targeting strategic acquisition by a major healthcare aggregator or PBM — targeting 5–8x ROIC.

Card Reference Details
Group
ACRX103
BIN
018935
PCN
ARX
Investor Presentation

The Full Picture

Full deck covering market opportunity, financials, partnership structure, and growth roadmap.

Official Stifel Funding Teaser Document
Detailed financial documents are available to qualified parties following NDA execution.
Request Access to Investment Documents

"This isn't a startup idea — it's a 20-year-old proven infrastructure seeking institutional capital to scale. With Stifel's advisory and ACRx's established PBM relationships, we're positioned to bring prescription savings to tens of millions more Americans while delivering institutional-grade returns."

LF
Lieutenant Colonel La Daryl Franklin, US Army (Ret.)
Team Eagle Founder
Get in Touch

Interested in this
opportunity?

Our team typically responds within 24 hours.

Direct Contact

Contact
LTC La Daryl Franklin, US Army (Ret.)
Team Eagle Founder
Advisor
Stifel Financial Corp.
Exclusive Financial Advisor & Placement Agent
Card Reference
Group: ACRX103 · BIN: 018935 · PCN: ARX
Detailed financial documents are available to qualified parties following NDA execution.
Request Access to Investment Documents Send Investment Inquiry

Quick Message